| Lutein and Oral Antioxidants Vitamin Supplements for Eye Conditions - prescribing guidance |
| Dry Eye Patient Information Leaflet |
GREEN* Self-care policy applies - advise patient to purchase where appropriate [Consider OTC/Self care]
|
| GREEN* Sno-Tears® 1.4% eye drops [Polyvinyl alcohol] |
| GREEN* Hypromellose 0.3% eye drops [AaproMel®, Dew Tear®, Lumecare®] |
| GREEN* Clinitas Gel® eye drops [Carbomer] |
| GREEN* HYLO-NIGHT® eye ointment (formerly VitA-POS® eye ointment) |
| GREEN* Lacri-Lube eye ointment |
| AMBER llube® eye drops |
| AMBER Hylo-Forte® eye drops (Consultant initiation only, reserved for dexterity issues) |
| [Self-care should be considered for mild/moderate dry eye not associated with a co-morbidity] |
| AMBER Systane® BALANCE lubricant eye drops (Specialist initiation only for Dry eye symptoms associated with |
| Meibomian gland dysfunction) |
| AMBER Ciclosporin (Ikervis®) unit dose eye drops - PRESCRIBE BY BRAND |
| Ciclosporin for treatment of dry eye disease that has not improved despite treatment with artificial tears is |
| recommended as an option by NICE. NICE TA369 |
AMBER Sodieye® 5% PF eye drops [Sodium Chloride 5% eye drops] PRESCRIBE BY BRAND
|
| AMBER Ciclosporin 0.1% eye drops 0.3ml unit dose (Verkazia®) -- Specialist initiation |
| RED Cross Linked Hyaluronic Acid & Co Enzyme Q10 (VisuXL®) Specialist use only |
| RED Carbomer single use eye gel (Viscotears® eye gel 0.6ml unit dose) NICU use only |
| |
Severe Dry Eye Only
|
| GREEN* Evolve HA® eye drops (preservative free) |
| [Self-care should be considered for mild/moderate dry eye not associated with a co-morbidity] |
| GREEN* Xailin HA® (sodium hyaluronate 0.2% Preservative Free) |
| [Self-care should be considered for mild/moderate dry eye not associated with a co-morbidity] |
| GREEN* Blink® Intensive Tears** 10ml and 0.4ml unit dose drops [Sodium hyaluronate 0.2%) |
| **[1st line choice hyaluronate in Primary Care] |
|
| BACK to main chapter |
| |
| 11.8.2 Ocular diagnostic and peri-operative preparations and photodynamic treatment |
| Ocular diagnostic preparations |
| AMBER Apraclonidine eye drops 0.5% |
| RED Fluorescein unit dose eye drops 1%, 2% |
| RED Proxymetacaine & fluorescein unit dose eye drops 0.5% |
| |
| Ocular peri-operative drugs |
| RED Balanced Salt Solution® |
| AMBER Diclofenac unit dose eye drops 0.1% |
| AMBER Ketorolac eye drops 0.5% |
| RED Miochol-E® solution for intra-ocular irrigation |
| RED Sodium hyaluronate injection 10mg/ml, 14mg/mL, 23mg/mL |
| |
| Approved for specific use in ophthalmolgy for volume enhancement of post-enucleation socket syndrome: |
| RED Hyaluronic acid injection (Restylane Sub-Q,® Juvederm®) |
| |
| Approved for use in opthalmology for those at higher risk of developing post-surgical cystoid macular oedema: |
| RED Bromfenac eye drops (Yellox®) |
| |
| Subfoveal choroidal neovas cullarisation |
| For use as per NICE guidance only. |
| RED Verteporfin injection 15mg vial |
| |
| 11.8.2.3 Subfoveal choroidal neovascularisation |
| Aflibercept |
| Approved for use in line with NICE guidance |
| NICE TA294 Wet age-related macular degeneration |
| NICE TA305 Visual Impairment caused by macular oedema secondary to central retinal vein occlusion |
| NICE TA346 Treatment for some people with sight problems caused by diabetic macular oedema |
| NICE TA486 An option for treating visual impairment because of myopic choroidal neovascularisation in adults, |
| only if the company provides aflibercept with the discount agreed in the patient access scheme |
| RED Aflibercept [Eylea 2mg/50microlitres solution for intravitreal injection] (NHS England Commissioned) |
| |
| Vitreomacular traction |
| Ocriplasmin for use in accordance with NICE guidance as an option in NICE TA297 |
| RED Ocriplasmin concentrate for solution for intravitreal injection 2.5mg/mL |
| (Each vial contains 0.5 mg of ocriplasmin in 0.2 ml solution) |
| |
| Ranibizumab |
| Approved for use in accordance with NICE guidance: |
| NICE TA283 Visual Impairment caused by Macular oedema secondary to retinal vein occlusion |
| NICE TA274 Diabetic macular oedema (DMO) |
| NICE TA155 Wet age-related macular degeneration (AMD) |
| NICE TA298 Choroidal neovascularisation associated with pathological myopia |
| |
| RED Ranibizumab solution for intravitreal injection 10mg/mL vial |
| |
| Brolucizumab |
| Wet age-related macular degeneration |
| NICE TA672 Recommended as an option for treating wet age-related macular degeneration in adults [as per guidance] |
| RED Brolucizumab solution for injection pre-filled syringes 19.8mg/0.165ml |
| CCG Commissioned Blueteq form required |
| |
Faricimab
|
| Wet age-related macular degeneration |
| NICE TA800 Recommended as an option for treating wet age-related macular degeneration in adults, only if: |
| > the eye has a best-corrected visual acuity between 6/12 and 6/96 |
| > there is no permanent structural damage ti the central fovea |
| > the lesion size is 12 disc areas or less in greatest linear dimension |
| > there are signs of recent disease progression (for example, blood vessel growth as shown by fluorescein |
| angiography, or recent visual acuity changes) |
| > the company provides faricimab according to the commercial arrangement |
| ICB Commissioned (formerly CCG) Blueteq form required |
